Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Indapamide + hydrochlorothiazide is a combination of two diuretic medications used to manage hypertension and fluid retention. Both drugs act on the distal convoluted tubule of the nephron in the kidney, promoting increased excretion of sodium and water, which reduces blood volume and lowers blood pressure. Indapamide is classified as a thiazide-like diuretic, while hydrochlorothiazide is a thiazide-type diuretic. The combination may be considered for patients who require enhanced diuresis or antihypertensive effect; however, clinical guidelines generally advise against using both simultaneously due to overlapping mechanisms and increased risk of adverse effects such as hypokalemia[3][7]. Each agent has demonstrated efficacy in lowering blood pressure and reducing cardiovascular risk when used alone or with other antihypertensives[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on indapamide + hydrochlorothiazide.